studies

breast cancer - HER2-positive, tucatinib plus trastuzumab plus capecitabine vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsHER2CLIMB, 2020 0.66 [0.50; 0.88] 0.66[0.50; 0.88]HER2CLIMB, 202010%612NAnot evaluable progression or deaths (PFS)detailed resultsHER2CLIMB, 2020 0.54 [0.42; 0.70] HER2CLIMB (patients with brain metastases), 2020 0.48 [0.34; 0.68] 0.52[0.42; 0.64]HER2CLIMB, 2020, HER2CLIMB (patients with brain metastases), 202020%771lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsHER2CLIMB, 2020 1.92 [0.77; 4.80] 1.92[0.77; 4.80]HER2CLIMB, 202010%601NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-21 02:29 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 718

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons